Ocular Therapeutix, Inc. (OCUL) shares climbed 9.24%, trading at $9.34, up $0.79, after the company reported fourth-quarter and full-year 2025 financial results that showed mixed revenue performance and highlighted ongoing clinical investment.
The company said its Q4 2025 net revenue was $13.3 million, down from $17.1 million a year earlier, and full-year 2025 net revenue totaled $52.0 million, declining from $63.7 million in 2024.
The results reflected decreases in product and collaboration revenue alongside increased research and development and operating expenses tied to clinical programs. Ocular Therapeutix reported a net loss of $64.7 million, or $0.29 loss per share, for the quarter.
On the day of the release, OCUL opened near $8.9, traded up to an intraday high around $9.75, and saw a low near $8.65, compared with its previous close of $8.55. Trading volume reflected increased investor focus on the earnings report and future clinical catalysts.
Ocular Therapeutix's 52-week range of approximately $5.78 to $16.44 underscores the biotech's volatility amid fluctuating revenue trends and clinical progress. Despite the revenue decline and quarterly loss, Ocular Therapeutix highlighted upcoming trial data and pipeline milestones, supporting investor interest in the company's long-term strategic direction.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.